Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bull Horn Holdings (BHSEU)
New Beginnings Acquisition (NBA.U)
CONX (CONXU)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Cerberus Telecom Acquisition (CTACU)
Upcoming IPO
OTR Acquisition (OTRAU)
Natural Order Acquisition (NOACU)
Priced IPO
Allegro MicroSystems, Inc. (ALGM)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Absolute Software (ABST)
EQT Corporation (EQT)
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
More companies

Kymera Therapeutics, Inc. (KYMR)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Their proprietary targeted protein degradation platform, which they refer to as Pegasus, allows them to discover highly selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. They believe that their small molecule protein degraders have significant advantages over existing therapies and allow them to address a large portion of the human genome that was previously intractable with traditional modalities. They focus on biological pathways that have been clinically validated but where key biological nodes/proteins have not been drugged or have been inadequately drugged. To date, they have utilized their Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and continue to apply their platform’s capabilities to additional therapeutic areas. Their initial programs include IRAK4, IRAKIMiD, and STAT3, which each focus on a single critical signaling node within the genetically and clinically validated interleukin-1 receptor/toll-like receptor, or IL-1R/TLR, and janus kinase/signal transducers and activators of transcription, or JAK/STAT, pathways. Their programs exemplify their focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs. They believe degrading these targets has the potential to treat multiple immune-inflammatory diseases, hematologic malignancies, and solid tumors.
Industry
BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
CEO CFO
Nello Mainolfi Bruce Jacobs
Employees Founded
55 2015

Contacts

Address: 200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472, US

Telephone: (857) 285-5300

Web page: http://www.kymeratx.com

IPO information

Expected Date 8/21/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $862.8
Revenues (MM) $9.5
Net Income (Loss) (MM) $-56.9

Voting

What do you think will happen with the KYMR share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 7.36
Shares Revised (MM) 8.7
Expected offer amount (MM) $125.12
Realized offer amount(MM) $174
Underwriters
Morgan Stanley/ BofA Securities/ Cowen/ Guggenheim Securities
CO-Managers
-

Sector: Healthcare

Tweets about $KYMR

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats